InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Discover the full record of transactions filed by Ainsworth Sean. Director active across 2 companies, notably Opus Genetics, Inc.. In total, 7 disclosures have been recorded. History available since 19 October 2022. The latest transaction was filed on 20 April 2026 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations
Ainsworth Sean is a director at Ocuphire Pharma, Inc. and Opus Genetics, Inc. The 4 filings on record, all within the sampled recent period from 2022-10-20 to 2025-05-02, concern attribution transactions, with sum_buy_eur at 0 and sum_sell_eur at 0.